Identification of Glioma-associated Antigen MUC 2-63 As CD44
Overview
Affiliations
Monoclonal antibody MUC 2-63 recognises neurogenic tumours and has been used successfully for radioimaging human malignant gliomas. We now show that the MUC 2-63 antigen has the same tissue distribution and molecular weight range as the CD44 antigen and confirm the identity of these two molecules in blocking studies using MUC 2-63 and the CD44 anti-framework antibody F10-44-2. Thus not only MUC 2-63 but also other anti-CD44 monoclonal antibodies should prove useful in imaging and, perhaps, therapy of brain tumours.
Monoclonal antibody ONS-M21 recognizes integrin alpha3 in gliomas and medulloblastomas.
Kishima H, Shimizu K, Tamura K, Miyao Y, Mabuchi E, Tominaga E Br J Cancer. 1999; 79(2):333-9.
PMID: 9888477 PMC: 2362207. DOI: 10.1038/sj.bjc.6690053.
Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system.
Baltuch G, Tribolet N, Van Meir E J Neurooncol. 1995; 26(3):191-8.
PMID: 8750185 DOI: 10.1007/BF01052622.